Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 18/20 | 0.62 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.47 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.47 |
| ▸ | BMP4 | P12644 | 3/20 | 0.47 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.47 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.47 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23989003 | 0.82 | ACVR1 (0.77) | ACVR1 | |
| SCHEMBL23988847 | 0.81 | ACVR1 (0.60) | ACVR1TGFBR2ACVR2ABMP4BMPR1B | |
| SCHEMBL23988861 | 0.79 | BMP4 (0.64) | ACVR1TGFBR2ACVR2ABMP4BMPR1B | |
| SCHEMBL23988699 | 0.78 | ACVR1 (0.69) | ACVR1BMPR1BBMPR1AACVR1BTGFBR1 | |
| SCHEMBL22075498 | 0.77 | ACVR1 (1.00) | ACVR1BMPR1BBMPR1AACVR1BTGFBR1 | |
| SCHEMBL22074625 | 0.77 | ACVR1 (0.86) | ACVR1BMPR1BBMPR1AACVR1BTGFBR1 | |
| SCHEMBL23988887 | 0.76 | ACVR1 (0.61) | ACVR1TGFBR2ACVR2ABMP4BMPR1B | |
| SCHEMBL23988890 | 0.75 | ACVR1 (0.61) | ACVR1 | |
| SCHEMBL23988744 | 0.73 | ACVR1 (0.60) | ACVR1 | |
| SCHEMBL23988869 | 0.73 | ACVR1 (0.58) | ACVR1TGFBR2BMP4BMPR1BKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021222875-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |